Literature DB >> 19703982

Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice.

D M Magnani1, J S Harms, M A Durward, G A Splitter.   

Abstract

Brucella spp. are gram-negative bacteria that cause the most frequent zoonotic disease worldwide, with more than 500,000 human infections yearly; however, no human vaccine is currently available. As with other intracellular organisms, cytotoxic mechanisms against infected cells are thought to have an important role in controlling infection and mediating long-term immunity. Live attenuated strains developed for use in animals elicit protection but retain unacceptable levels of virulence. Thus, the optimal design for a brucellosis vaccine requires a nonliving vaccine that confers effective immunity. Historically, inactivation methods such as chemical or heat treatment successfully impair Brucella reproductive capacity; nevertheless, metabolically inactive vaccines (subunit or killed) present very limited efficacy. Hence, we hypothesized that bacterial metabolism plays a major role in creating the proper antigenic and adjuvant properties required for efficient triggering of protective responses. Here, we demonstrate that inactivation of Brucella melitensis by gamma-irradiation inhibited its replication capability and yet retained live-Brucella protective features. Irradiated Brucella possessed metabolic and transcriptional activity, persisted in macrophages, generated antigen-specific cytotoxic T cells, and protected mice against virulent bacterial challenge, without signs of residual virulence. In conclusion, pathogen metabolic activity has a positive role in shaping protective responses, and the generation of inactivated and yet metabolically active microbes is a promising strategy for safely vaccinating against intracellular organisms such as B. melitensis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703982      PMCID: PMC2772552          DOI: 10.1128/IAI.00231-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

Review 1.  Molecular biology of bacterial bioluminescence.

Authors:  E A Meighen
Journal:  Microbiol Rev       Date:  1991-03

Review 2.  Vaccination against Brucella.

Authors:  P Nicoletti
Journal:  Adv Biotechnol Processes       Date:  1990

3.  Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice.

Authors:  J A Montaraz; A J Winter
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

Review 4.  Immunity to intracellular bacteria.

Authors:  S H Kaufmann
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 5.  A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats.

Authors:  J M Blasco
Journal:  Prev Vet Med       Date:  1997-08       Impact factor: 2.670

6.  Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus.

Authors:  L N Araya; P H Elzer; G E Rowe; F M Enright; A J Winter
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

7.  Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.

Authors:  T Matsuyama; T Kimura; M Kitagawa; K Pfeffer; T Kawakami; N Watanabe; T M Kündig; R Amakawa; K Kishihara; A Wakeham
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

8.  Comparison of Brucella abortus antigen preparations for in vitro stimulation of immune bovine T-lymphocyte cell lines.

Authors:  J H Wyckoff; J L Howland; A W Confer
Journal:  Vet Immunol Immunopathol       Date:  1993-02       Impact factor: 2.046

9.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  CD8+ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice.

Authors:  S C Oliveira; G A Splitter
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

View more
  22 in total

1.  Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; Y Fan; M M Kahl-McDonagh; T A Ficht
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

2.  Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.

Authors:  Fengjia Chen; Ho Seong Seo; Hyun Jung Ji; Eunji Yang; Jung Ah Choi; Jae Seung Yang; Manki Song; Seung Hyun Han; Sangyong Lim; Jae Hyang Lim; Ki Bum Ahn
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

3.  Virulent Francisella tularensis destabilize host mRNA to rapidly suppress inflammation.

Authors:  Timothy J Bauler; Jennifer C Chase; Tara D Wehrly; Catharine M Bosio
Journal:  J Innate Immun       Date:  2014-05-27       Impact factor: 7.349

4.  Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge.

Authors:  Dina Moustafa; Virendra K Garg; Neeta Jain; Nammalwar Sriranganathan; Ramesh Vemulapalli
Journal:  Vaccine       Date:  2010-11-23       Impact factor: 3.641

5.  Discordant Brucella melitensis antigens yield cognate CD8+ T cells in vivo.

Authors:  Marina A Durward; Jerome Harms; Diogo M Magnani; Linda Eskra; Gary A Splitter
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

Review 6.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

Review 7.  The role of nuclear technologies in the diagnosis and control of livestock diseases--a review.

Authors:  Gerrit J Viljoen; Antony G Luckins
Journal:  Trop Anim Health Prod       Date:  2012-10       Impact factor: 1.559

8.  An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice.

Authors:  Karina A Pasquevich; Andrés E Ibañez; Lorena M Coria; Clara García Samartino; Silvia M Estein; Astrid Zwerdling; Paula Barrionuevo; Fernanda S Oliveira; Christine Seither; Heribert Warzecha; Sergio C Oliveira; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

9.  Active evasion of CTL mediated killing and low quality responding CD8+ T cells contribute to persistence of brucellosis.

Authors:  Marina Durward; Girish Radhakrishnan; Jerome Harms; Claire Bareiss; Diogo Magnani; Gary A Splitter
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 10.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.